Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial

Tom Freeman, Chandni Hindocha, Gianluca Baio, Natacha Shaban, Emily Thomas, Danica Astbury, Abigail Freeman, Rachel Hannah Lees, Sam Craft, Paul Morrison, Michael Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia Morgan, Ali Mofeez, H Valerie Curran

Research output: Contribution to journalArticle

Original languageEnglish
JournalThe Lancet Psychiatry
Publication statusAcceptance date - 2 Jun 2020

Cite this

Freeman, T., Hindocha, C., Baio, G., Shaban, N., Thomas, E., Astbury, D., Freeman, A., Lees, R. H., Craft, S., Morrison, P., Bloomfield, M., O'Ryan, D., Kinghorn, J., Morgan, C., Mofeez, A., & Curran, H. V. (Accepted/In press). Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial. The Lancet Psychiatry.